RESEARCHER PROFILE

Chadi Nabhan

← Back to University of South Carolina

C

University of South Carolina

Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia ResearchAcute Lymphoblastic Leukemia researchViral-associated cancers and disordersCNS Lymphoma Diagnosis and Treatment

Chadi Nabhan works in Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research, Acute Lymphoblastic Leukemia research, Viral-associated cancers and disorders, CNS Lymphoma Diagnosis and Treatment. Recorded institutional associations include University of South Carolina.

278Publications
5,174Citations
38H-index

Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.

Selected research works

Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.

  1. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis

    2014 · 467 citations
  2. Outcomes of COVID-19 in patients with CLL: a multicenter international experience

    2020 · 305 citations
  3. Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients

    2017 · 229 citations
  4. Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience

    2016 · 193 citations
  5. Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States

    2018 · 165 citations
  6. A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era

    2011 · 164 citations
  7. Chronic Lymphocytic Leukemia

    2014 · 158 citations
  8. Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy

    2014 · 141 citations
  9. Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL

    2017 · 133 citations
  10. Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy

    2020 · 117 citations
  11. MYC‐associated and double‐hit lymphomas: A review of pathobiology, prognosis, and therapeutic approaches

    2014 · 98 citations
  12. Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices

    2012 · 98 citations
  13. Prevalence and characteristics of central nervous system involvement by chronic lymphocytic leukemia

    2016 · 98 citations
  14. Analysis of very elderly (≥80 years) non‐hodgkin lymphoma: impact of functional status and co‐morbidities on outcome

    2011 · 96 citations
  15. Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice

    2019 · 90 citations
  16. Classifying Cytogenetics in Patients with Acute Myelogenous Leukemia in Complete Remission Undergoing Allogeneic Transplantation: A Center for International Blood and Marrow Transplant Research Study

    2011 · 87 citations
  17. Gray zone lymphoma with features intermediate between classical H odgkin lymphoma and diffuse large B ‐cell lymphoma: C haracteristics, outcomes, and prognostication among a large multicenter cohort

    2015 · 85 citations
  18. Phase II pilot trial of gemtuzumab ozogamicin (GO) as first line therapy in acute myeloid leukemia patients age 65 or older

    2004 · 75 citations
  19. Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma—a “real world” study

    2017 · 70 citations
  20. Outcomes of front‐line ibrutinib treated CLL patients excluded from landmark clinical trial

    2018 · 69 citations
  21. A Pilot Trial of Rituximab and Alemtuzumab Combination Therapy in Patients with Relapsed and/or Refractory Chronic Lymphocytic Leukemia (CLL)

    2004 · 68 citations
  22. Disease characteristics, treatment patterns, prognosis, outcomes and lymphoma‐related mortality in elderly follicular lymphoma in the United States

    2015 · 67 citations
  23. Predicting Prognosis in Chronic Lymphocytic Leukemia in the Contemporary Era

    2015 · 63 citations
  24. Comparable outcomes in chronic lymphocytic leukaemia ( CLL ) patients treated with reduced‐dose ibrutinib: results from a multi‐centre study

    2017 · 63 citations
  25. Comparative effectiveness of anthracycline-containing chemotherapy in United States veterans age 80 and older with diffuse large B-cell lymphoma

    2015 · 61 citations

← Return to the university profile